

09/676,034

FILE 'HCAPLUS' ENTERED AT 10:00:29 ON 25 JAN 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 10:00:29 ON 25 JAN 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> d his

(FILE 'HOME' ENTERED AT 09:46:20 ON 25 JAN 2004)

FILE 'REGISTRY' ENTERED AT 09:58:48 ON 25 JAN 2004

L1 STRUCTURE UPLOADED  
L2 0 S L1 SSS SAM  
L3 1 S L1 SSS FULL

FILE 'HCAPLUS, USPATFULL' ENTERED AT 09:59:44 ON 25 JAN 2004

L4 6 S L3

FILE 'REGISTRY' ENTERED AT 09:59:59 ON 25 JAN 2004

L5 1 DUP REM L3 (0 DUPLICATES REMOVED)

FILE 'HCAPLUS, USPATFULL' ENTERED AT 10:00:29 ON 25 JAN 2004


=> dup rem l4

PROCESSING COMPLETED FOR L4

L6 3 DUP REM L4 (3 DUPLICATES REMOVED)

=> d l6 abs ibib hitstr 1-3

L6 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1  
GI



I

AB Title compds., e.g. [I; R = O<sub>2</sub>CR<sub>1</sub>; R<sub>1</sub> = alkyl, haloalkyl, hydroxyalkyl, alkenyl, haloalkenyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkyl, (substituted) Ph, PhNH, PhCH<sub>2</sub>, etc.], were prepd. Thus, Me 2-amino-5-hydroxybenzimidazole carbamate and 3,5,5-trimethylhexanoyl chloride were stirred in THF at 23-40.degree. to give I (R = O<sub>2</sub>CCH<sub>2</sub>CHMeCH<sub>2</sub>CMe<sub>3</sub>). The latter inhibited human colon carcinoma with IC<sub>50</sub> = 15.8 .mu.M.

ACCESSION NUMBER: 2002:889200 HCAPLUS

DOCUMENT NUMBER: 137:370090

TITLE: Preparation of benzimidazolecarbamates for treatment of cancer or viral infections

INVENTOR(S): Quada, James C., Jr.; Agyin, Joseph K.; Camden, James

DELACROIX

09/676,034

PATENT ASSIGNEE(S): Berger  
SOURCE: The Procter & Gamble Company, USA  
U.S., 20 pp., Cont.-in-part of U.S. Ser. No. 857,811.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 6  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6482843	B1	20021119	US 2000-676407	20000929
US 6506783	B1	20030114	US 1997-857811	19970516
BR 9714634	A	20000523	BR 1997-14634	19971126
CN 1254282	A	20000524	CN 1997-182190	19971126
US 6077862	A	20000620	US 1999-259969	19990301
AU 763272	B2	20030717	AU 2001-37094	20010418

PRIORITY APPLN. INFO.:  
US 1997-857811 A2 19970516  
AU 1998-74027 A3 19971126  
WO 1997-US24565 W 19971126


OTHER SOURCE(S): MARPAT 137:370090

IT 443685-81-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of benzimidazolecarbamates for treatment of cancer or viral infections)


RN 443685-81-2 HCAPLUS

CN Hexanoic acid, 3,5,5-trimethyl-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-4-yl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 106 THERE ARE 106 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 2  
GI



I



II

DELACROIX

09/676,034

AB The title compds. [I (R = OCORa; Ra = (un)substituted Ph), II (R = CONR1R2, CO2R1, OCOR1, NHCOR1; R1 = alkyl, haloalkyl, cycloalkyl, etc.; R2 = H, alkyl)] were prepd. Thus, reacting Me 2-amino-5-hydroxybenzimidazolecarbamate with 3,5,5-trimethylhexanoyl chloride in THF afforded 57% I [R = OCOCH2CHMeCH2CMe3] which showed IC50 of 20.1 .mu.M and IC50 of 15.8 .mu.M for growth inhibition of B16 murine melanoma cells and H29 human colon cancer cells, resp. Such compds. I may be used in combination with a chemotherapeutic agent and/or a potentiator.

ACCESSION NUMBER: 2002:551611 HCAPLUS  
DOCUMENT NUMBER: 137:109276  
TITLE: Preparation of methyl 1H-benzimidazole-2-carbamates for treating cancer or viral infections  
INVENTOR(S): Camden, James Berger; Agyin, Joseph K.; Quada, James C., Jr.  
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA  
SOURCE: U.S., 19 pp., Cont. of U.S. Ser. No. 857,811.,  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 6  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6423736	B1	20020723	US 2000-676409	20000929
US 6506783	B1	20030114	US 1997-857811	19970516
BR 9714634	A	20000523	BR 1997-14634	19971126
CN 1254282	A	20000524	CN 1997-182190	19971126
US 6077862	A	20000620	US 1999-259969	19990301
AU 763272	B2	20030717	AU 2001-37094	20010418

PRIORITY APPLN. INFO.:  
US 1997-857811 A2 19970516  
AU 1998-74027 A3 19971126  
WO 1997-US24565 W 19971126

OTHER SOURCE(S): MARPAT 137:109276


IT 443685-81-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of Me benzimidazole-2-carbamates for treating cancer or viral infections)

RN 443685-81-2 HCAPLUS

CN Hexanoic acid, 3,5,5-trimethyl-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-4-yl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 119 THERE ARE 119 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


DELACROIX

09/676,034

L6 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 3  
GI



I



II

AB The title compds. [I (R = OCORa; Ra = (un)substituted Ph), II (R = CONR1R2, CO2R1, OCOR1, NHCOR1; R1 = alkyl, haloalkyl, cycloalkyl, etc.; R2 = H, alkyl)] were prepd. Thus, reacting Me 2-amino-5-hydroxybenzimidazolecarbamate with 3,5,5-trimethylhexanoyl chloride in THF afforded 57% I [R = OCOCH2CHMeCH2CMe3] which showed IC50 of 20.1 .mu.M and IC50 of 15.8 .mu.M for growth inhibition of B16 murine melanoma cells and H29 human colon cancer cells, resp. Such compds. I may be used in combination with a chemotherapeutic agent and/or a potentiator such as DNA-interactive agent, an antimetabolite, a tubulin-interactive agent, a hormonal agent, an antihormonal antigen, and an adrenal corticosteroid.

ACCESSION NUMBER: 2002:551610 HCAPLUS  
DOCUMENT NUMBER: 137:109275  
TITLE: Preparation of methyl 1H-benzimidazole-2-carbamates for treating cancer or viral infections  
INVENTOR(S): Camden, James Berger; Quada, James C., Jr.; Agyin, Joseph K.  
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA  
SOURCE: U.S., 17 pp., Cont. of U.S. Ser. No. 857,811.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 6  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6423735	B1	20020723	US 2000-676029	20000929
US 6506783	B1	20030114	US 1997-857811	19970516
BR 9714634	A	20000523	BR 1997-14634	19971126
CN 1254282	A	20000524	CN 1997-182190	19971126
US 6077862	A	20000620	US 1999-259969	19990301
AU 763272	B2	20030717	AU 2001-37094	20010418

PRIORITY APPLN. INFO.:  
US 1997-857811 A2 19970516  
AU 1998-74027 A3 19971126  
WO 1997-US24565 W 19971126

OTHER SOURCE(S): MARPAT 137:109275

IT 443685-81-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of Me benzimidazole-2-carbamates for treating cancer or viral infections)

RN 443685-81-2 HCAPLUS

CN Hexanoic acid, 3,5,5-trimethyl-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-4-yl ester (9CI) (CA INDEX NAME)

DELACROIX

09/676,034



REFERENCE COUNT:

52

THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

DELACROIX